Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
Document Type
Journal Article
Publication Date
8-1-2022
Journal
JCO global oncology
Volume
8
DOI
10.1200/GO.21.00380
Abstract
PURPOSE: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America. METHODS: We retrospectively analyzed patients with WM diagnosed between 1991 and 2019 from 24 centers in seven Latin American countries. The study outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS: We identified 159 cases (median age 67 years, male 62%). Most patients (95%) were symptomatic at diagnosis. The International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients were tested for MYD88, with 89% (n = 24 of 27) carrying the mutation. First-line and second-line therapies were administered to 142 (89%) and 53 (33%) patients, respectively. Chemoimmunotherapy was the most commonly used first-line (66%) and second-line (45%) approach; only 18 (11%) patients received ibrutinib. With a median follow-up of 69 months, the 5-year OS rate was 81%. In treated patients, the 5-year OS and PFS rates were 78% and 59%, respectively. High-risk IPSSWM at treatment initiation was an independent risk factor for OS (adjusted hazard ratio: 4.73, 95% CI, 1.67 to 13.41, = .003) and PFS (adjusted hazard ratio: 2.43, 95% CI, 1.31 to 4.50, = .005). CONCLUSION: In Latin America, the management of WM is heterogeneous, with limited access to molecular testing and novel agents. However, outcomes were similar to those reported internationally. We validated the IPSSWM score as a prognostic factor for OS and PFS. There is an unmet need to improve access to recommended diagnostic approaches and therapies in Latin America.
APA Citation
Riva, Eloísa; Duarte, Patricio José; Valcárcel, Bryan; Remaggi, Guillermina; Murrieta, Ivan; Corzo, Ariel; Del Carpio, Daniel; Peña, Camila; Vásquez, Jule; Bove, Virginia; Teixeira, Larissa; Fleury-Perini, Guilherme; Yantorno, Sebastian; Samánez, César; Lopresti, Sergio; Altamirano, Milagros; Villela, Luis; Ruiz-Arguelles, Guillermo J.; Ruiz-Delgado, Guillermo J.; Montaño, Efreen; Verri, Verónica; Zamora Pérez, Elia; Pérez Jacobo, Fernando; Idrobo, Henry; Martínez-Cordero, Humberto; Beltran, Brady E.; Ramírez, Jhoanna; Castillo, Jorge J.; and Malpica Castillo, Luis E., "Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study" (2022). GW Authored Works. Paper 1558.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/1558
Department
Public Health Student Works